<DOC>
	<DOCNO>NCT02579863</DOCNO>
	<brief_summary>The purpose study compare efficacy lenalidomide low dose dexamethasone pembrolizumab ( MK-3475 ) lenalidomide low dose dexamethasone without pembrolizumab term progression-free survival ( PFS ) participants newly diagnose treatment-naïve multiple myeloma ineligible autologous stem cell transplant ( Auto-SCT ) .</brief_summary>
	<brief_title>Study Lenalidomide Dexamethasone With Without Pembrolizumab ( MK-3475 ) Participants With Newly Diagnosed Treatment Naive Multiple Myeloma ( MK-3475-185/KEYNOTE-185 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Confirmed diagnosis active multiple myeloma measurable disease . Ineligible receive treatment autoSCT due age ( ≥65 year old ) significant coexist medical condition ( cardiac , renal , pulmonary hepatic dysfunction ) , likely negative impact tolerability autoSCT . Participants &lt; 65 year age refuse autoSCT eligible study . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Female participant childbearing potential must 2 negative urine pregnancy test ( sensitivity least 25 Milliinternational units/Milliliter ) within 10 14 day within 24 hour prior receive study medication . Female participant childbearing potential must agree use adequate contraception 28 day prior study start , continue throughout study , 28 day last dose lenalidomide ( 120 day last dose pembrolizumab ) . Male participant childbearing potential must agree use adequate contraception first dose study medication , continue throughout study , 28 day last dose lenalidomide ( 120 day last dose pembrolizumab ) . Has undergone prior allogeneic hematopoetic stem cell transplantation within last 5 year . Has peripheral neuropathy ≥ Grade 2 . Has know additional malignancy progress require active treatment within last 5 year ( except basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy ) . Has history noninfectious pneumonitis require steroid current pneumonitis Has receive prior therapy antiprogrammed cell death 1 receptor ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Has know Human Immunodeficiency Virus ( HIV ) , know , active Hepatitis B ( HBV ) , know , active Hepatitis C ( HCV ) infection . Is unable unwilling undergo thromboembolic prophylaxis include , clinically indicate , aspirin , Coumadin ( warfarin ) lowmolecular weight heparin . Has lactose intolerance . Has invasive fungal infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>